Intelligent Bio Solutions Amends 10-K for Executive Comp & Governance
Intelligent Bio Solutions Inc. filed Amendment No. 1 to its 10-K, primarily to revise disclosures related to executive compensation, related-party transactions, and exhibits. The amendment clarifies capital raising transactions involving significant shareholders and the approval process for related-party transactions. It also details executive compensation for fiscal years 2025 and 2026, including salary, stock awards, and bonuses for CEO Harry Simeonidis and CFO Spiro Sakiris. Employment agreements were amended to adjust non-compete terms and enhance severance benefits, with specific provisions for termination and change in control scenarios. Additionally, the filing outlines the granting of restricted stock awards under the 2019 Long Term Incentive Plan, including performance-vesting awards tied to clinical trial, regulatory submission, and commercial milestones.
Key Highlights
- Intelligent Bio Solutions Inc. filed an amendment to its 10-K, revising Items 11, 13, and 15.
- The amendment removes duplicate disclosure regarding Outstanding Equity Awards at Fiscal Year End.
- Item 13 was revised to add disclosure regarding capital raising transactions involving major shareholders and clarify related party transaction approval processes.
- The Exhibit Index in Item 15 was updated to correct duplicate entries and reflect the Amended and Restated Certificate of Incorporation.
- New Sarbanes-Oxley Section 302 certifications were included, with specific paragraphs omitted as no financial statements were amended.
- Executive compensation details for fiscal years 2026 and 2025 for Named Executive Officers Harry Simeonidis and Spiro Sakiris are provided.
- Amendments to employment agreements for Simeonidis and Sakiris were approved on June 30, 2025, modifying non-compete clauses and severance benefits.
- Restricted stock awards, both time-vesting and performance-vesting, were granted on March 18, 2026, under the 2019 Long Term Incentive Plan.
Price Impact
More from INBS
More in Corporate Governance